Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency
NCT04227678Recruiting
- Sponsor
- Université de Sherbrooke
- Start
- Dec 2019
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of heparin in lipoprotein lipase deficiency (LPLD) (4 arms), sponsored by Université de Sherbrooke. Primary endpoints: Organ-specific Dietary Fatty Acid (DFA) partitioning at 2 months and Myocardial DFA uptake at 2 months. Started Dec 2019; status: recruiting.
02
Drugs
heparin
03
Conditions
lipoprotein lipase deficiency (LPLD)
Beyond the preview
Go deeper on NCT04227678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04227678.